 Bradley Dixon
Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atypical Hemolytic Uremic Syndrome | 8 | 2024 | 21 | 2.180 |
Why?
| | Glomerulonephritis, Membranoproliferative | 4 | 2026 | 25 | 1.570 |
Why?
| | Kidney Diseases | 6 | 2025 | 427 | 1.210 |
Why?
| | Complement C3 | 3 | 2026 | 191 | 1.150 |
Why?
| | Thrombotic Microangiopathies | 6 | 2020 | 19 | 1.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 9 | 2024 | 985 | 0.690 |
Why?
| | Tuberous Sclerosis | 4 | 2017 | 56 | 0.630 |
Why?
| | TRPM Cation Channels | 2 | 2019 | 75 | 0.620 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2019 | 675 | 0.590 |
Why?
| | Hemolytic-Uremic Syndrome | 1 | 2019 | 15 | 0.580 |
Why?
| | Nephrotic Syndrome | 3 | 2025 | 44 | 0.580 |
Why?
| | Kidney | 10 | 2025 | 1495 | 0.580 |
Why?
| | Lupus Nephritis | 3 | 2025 | 70 | 0.580 |
Why?
| | Proteinuria | 4 | 2026 | 102 | 0.550 |
Why?
| | Renal Insufficiency, Chronic | 4 | 2026 | 653 | 0.530 |
Why?
| | Complement System Proteins | 5 | 2025 | 316 | 0.530 |
Why?
| | Osmoregulation | 1 | 2017 | 4 | 0.510 |
Why?
| | DNA Damage | 2 | 2011 | 430 | 0.510 |
Why?
| | Complement Inactivating Agents | 4 | 2025 | 74 | 0.510 |
Why?
| | Kidney Tubules, Collecting | 1 | 2017 | 27 | 0.510 |
Why?
| | Osmotic Pressure | 1 | 2017 | 39 | 0.510 |
Why?
| | Immunosuppressive Agents | 6 | 2025 | 846 | 0.480 |
Why?
| | Hypertension | 4 | 2026 | 1263 | 0.460 |
Why?
| | Autoimmunity | 1 | 2020 | 926 | 0.420 |
Why?
| | Peptides, Cyclic | 2 | 2026 | 275 | 0.420 |
Why?
| | Acute Kidney Injury | 4 | 2023 | 865 | 0.400 |
Why?
| | Autoantibodies | 2 | 2020 | 1501 | 0.390 |
Why?
| | Antihypertensive Agents | 2 | 2026 | 510 | 0.350 |
Why?
| | Epithelial Cells | 2 | 2019 | 1125 | 0.340 |
Why?
| | Urothelium | 1 | 2011 | 33 | 0.330 |
Why?
| | Cell Line | 3 | 2019 | 2882 | 0.330 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2026 | 114 | 0.330 |
Why?
| | Kidney Transplantation | 4 | 2024 | 704 | 0.300 |
Why?
| | Osmolar Concentration | 1 | 2009 | 167 | 0.300 |
Why?
| | Pyrimidines | 3 | 2022 | 532 | 0.280 |
Why?
| | RecQ Helicases | 1 | 2008 | 9 | 0.280 |
Why?
| | Angiomyolipoma | 3 | 2014 | 21 | 0.280 |
Why?
| | Humans | 44 | 2026 | 144759 | 0.270 |
Why?
| | Cell Cycle | 1 | 2011 | 596 | 0.270 |
Why?
| | Complement Activation | 3 | 2025 | 411 | 0.260 |
Why?
| | Purines | 1 | 2008 | 187 | 0.250 |
Why?
| | Urinary Bladder | 1 | 2009 | 194 | 0.250 |
Why?
| | Child | 22 | 2026 | 22633 | 0.250 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2026 | 221 | 0.240 |
Why?
| | Benzoates | 1 | 2026 | 50 | 0.240 |
Why?
| | Escherichia coli Proteins | 1 | 2008 | 206 | 0.240 |
Why?
| | Nephrology | 2 | 2024 | 60 | 0.230 |
Why?
| | Treatment Outcome | 10 | 2026 | 11679 | 0.230 |
Why?
| | Induction Chemotherapy | 1 | 2025 | 87 | 0.230 |
Why?
| | Prenatal Injuries | 1 | 2005 | 1 | 0.230 |
Why?
| | Hypertension, Renal | 1 | 2005 | 15 | 0.220 |
Why?
| | Calcium Channel Blockers | 1 | 2026 | 165 | 0.220 |
Why?
| | Retroperitoneal Space | 1 | 2005 | 18 | 0.220 |
Why?
| | Nephrocalcinosis | 1 | 2024 | 13 | 0.220 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2024 | 6 | 0.220 |
Why?
| | Hematoma | 1 | 2005 | 59 | 0.220 |
Why?
| | Piperidines | 1 | 2026 | 217 | 0.210 |
Why?
| | Kidney Diseases, Cystic | 2 | 2017 | 24 | 0.210 |
Why?
| | Adolescent | 14 | 2026 | 22428 | 0.210 |
Why?
| | Rituximab | 1 | 2025 | 209 | 0.210 |
Why?
| | Polycystic Kidney Diseases | 1 | 2005 | 71 | 0.210 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2024 | 43 | 0.210 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2017 | 29 | 0.200 |
Why?
| | Kidney Neoplasms | 3 | 2014 | 412 | 0.200 |
Why?
| | Disease Management | 2 | 2020 | 645 | 0.200 |
Why?
| | Glomerular Filtration Rate | 2 | 2024 | 760 | 0.200 |
Why?
| | Nephritis | 1 | 2023 | 22 | 0.200 |
Why?
| | Slipped Capital Femoral Epiphyses | 1 | 2022 | 7 | 0.190 |
Why?
| | Femur Head Necrosis | 1 | 2022 | 15 | 0.190 |
Why?
| | Delphi Technique | 1 | 2024 | 329 | 0.190 |
Why?
| | Pharmacists | 1 | 2025 | 240 | 0.180 |
Why?
| | Terminology as Topic | 1 | 2024 | 255 | 0.180 |
Why?
| | Complement Factor B | 1 | 2023 | 106 | 0.180 |
Why?
| | Arthritis, Juvenile | 1 | 2022 | 56 | 0.180 |
Why?
| | Self-Management | 1 | 2025 | 201 | 0.180 |
Why?
| | Indoles | 1 | 2026 | 501 | 0.180 |
Why?
| | Wounds, Nonpenetrating | 1 | 2005 | 316 | 0.170 |
Why?
| | DNA | 1 | 2008 | 1463 | 0.170 |
Why?
| | Rheumatology | 1 | 2022 | 133 | 0.170 |
Why?
| | Recurrence | 1 | 2024 | 1135 | 0.170 |
Why?
| | Male | 18 | 2026 | 72315 | 0.150 |
Why?
| | Female | 19 | 2026 | 78271 | 0.150 |
Why?
| | Glomerulonephritis | 1 | 2019 | 45 | 0.150 |
Why?
| | Child, Preschool | 10 | 2026 | 11787 | 0.150 |
Why?
| | Tumor Suppressor Proteins | 2 | 2012 | 321 | 0.150 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 239 | 0.150 |
Why?
| | Plasma Exchange | 1 | 2019 | 18 | 0.150 |
Why?
| | Cilia | 2 | 2019 | 173 | 0.150 |
Why?
| | Hirschsprung Disease | 1 | 2020 | 91 | 0.140 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2182 | 0.140 |
Why?
| | Renal Dialysis | 2 | 2022 | 462 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2020 | 348 | 0.140 |
Why?
| | TRPP Cation Channels | 1 | 2019 | 74 | 0.140 |
Why?
| | Electronic Health Records | 3 | 2023 | 1173 | 0.140 |
Why?
| | Plasmapheresis | 1 | 2018 | 22 | 0.140 |
Why?
| | Critical Illness | 2 | 2023 | 891 | 0.140 |
Why?
| | Renal Replacement Therapy | 1 | 2019 | 100 | 0.140 |
Why?
| | Escherichia coli Infections | 1 | 2019 | 129 | 0.140 |
Why?
| | Sirolimus | 2 | 2017 | 281 | 0.130 |
Why?
| | Fluid Therapy | 1 | 2019 | 147 | 0.130 |
Why?
| | Blood Component Transfusion | 1 | 2018 | 103 | 0.130 |
Why?
| | Hydroxyprostaglandin Dehydrogenases | 1 | 2017 | 3 | 0.130 |
Why?
| | Risk Factors | 4 | 2024 | 10779 | 0.130 |
Why?
| | GABA Plasma Membrane Transport Proteins | 1 | 2017 | 7 | 0.130 |
Why?
| | Transfection | 2 | 2017 | 940 | 0.130 |
Why?
| | Saline Solution, Hypertonic | 1 | 2017 | 42 | 0.130 |
Why?
| | TRPV Cation Channels | 1 | 2017 | 43 | 0.120 |
Why?
| | Erythrocyte Transfusion | 1 | 2019 | 231 | 0.120 |
Why?
| | Plasma | 1 | 2018 | 225 | 0.120 |
Why?
| | Streptococcal Infections | 1 | 2019 | 168 | 0.120 |
Why?
| | Autoimmune Diseases | 1 | 2020 | 463 | 0.120 |
Why?
| | Gene Editing | 1 | 2017 | 93 | 0.120 |
Why?
| | Patient Selection | 1 | 2019 | 719 | 0.110 |
Why?
| | CRISPR-Cas Systems | 1 | 2017 | 170 | 0.110 |
Why?
| | Cytomegalovirus Infections | 1 | 2017 | 206 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1489 | 0.110 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 186 | 0.110 |
Why?
| | Pericytes | 1 | 2014 | 36 | 0.100 |
Why?
| | Complement Membrane Attack Complex | 1 | 2013 | 38 | 0.100 |
Why?
| | Adult | 7 | 2026 | 40449 | 0.100 |
Why?
| | Caregivers | 1 | 2022 | 1049 | 0.100 |
Why?
| | Infant | 6 | 2025 | 10034 | 0.090 |
Why?
| | Complement Factor D | 2 | 2022 | 28 | 0.090 |
Why?
| | Transplantation, Autologous | 2 | 2013 | 290 | 0.090 |
Why?
| | Indazoles | 2 | 2022 | 80 | 0.090 |
Why?
| | Complement Pathway, Alternative | 1 | 2013 | 122 | 0.090 |
Why?
| | Proline | 2 | 2022 | 83 | 0.090 |
Why?
| | Young Adult | 6 | 2026 | 14105 | 0.090 |
Why?
| | Aminopyridines | 2 | 2022 | 127 | 0.090 |
Why?
| | Hematologic Neoplasms | 1 | 2013 | 161 | 0.090 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2012 | 120 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2025 | 17066 | 0.090 |
Why?
| | Antigens, Polyomavirus Transforming | 1 | 2011 | 15 | 0.080 |
Why?
| | Biomarkers | 4 | 2025 | 4271 | 0.080 |
Why?
| | Nephrolithiasis | 1 | 2010 | 9 | 0.080 |
Why?
| | Creatinine | 2 | 2025 | 506 | 0.080 |
Why?
| | Histoplasmosis | 1 | 2010 | 15 | 0.080 |
Why?
| | Prognosis | 1 | 2019 | 4282 | 0.080 |
Why?
| | Biopsy | 2 | 2025 | 1075 | 0.070 |
Why?
| | Mice | 3 | 2019 | 18339 | 0.070 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2009 | 56 | 0.070 |
Why?
| | Organ Specificity | 1 | 2009 | 312 | 0.070 |
Why?
| | Kanamycin Resistance | 1 | 2008 | 2 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2014 | 3540 | 0.070 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2008 | 27 | 0.070 |
Why?
| | Prospective Studies | 4 | 2023 | 7990 | 0.070 |
Why?
| | Mutation | 2 | 2010 | 4089 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 965 | 0.070 |
Why?
| | Stomach Neoplasms | 1 | 2009 | 126 | 0.070 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2011 | 255 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2879 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2010 | 168 | 0.070 |
Why?
| | Blood Pressure | 2 | 2025 | 1769 | 0.070 |
Why?
| | Stress, Mechanical | 1 | 2009 | 494 | 0.060 |
Why?
| | Plasmids | 1 | 2008 | 379 | 0.060 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 259 | 0.060 |
Why?
| | DNA Repair | 1 | 2009 | 256 | 0.060 |
Why?
| | DNA, Bacterial | 1 | 2008 | 342 | 0.060 |
Why?
| | DNA Replication | 1 | 2008 | 251 | 0.060 |
Why?
| | Signal Transduction | 2 | 2017 | 5226 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5992 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1187 | 0.060 |
Why?
| | Antigens, CD20 | 1 | 2025 | 35 | 0.060 |
Why?
| | Cyclophosphamide | 1 | 2025 | 266 | 0.060 |
Why?
| | Disease Progression | 2 | 2023 | 2847 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 120 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2025 | 117 | 0.060 |
Why?
| | Kidney Glomerulus | 1 | 2025 | 128 | 0.060 |
Why?
| | Nucleic Acid Conformation | 1 | 2008 | 726 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2026 | 170 | 0.050 |
Why?
| | Repressor Proteins | 1 | 2008 | 437 | 0.050 |
Why?
| | Apoptosis | 2 | 2012 | 2430 | 0.050 |
Why?
| | Animals | 3 | 2019 | 38058 | 0.050 |
Why?
| | Escherichia coli | 1 | 2008 | 854 | 0.050 |
Why?
| | Remission Induction | 1 | 2024 | 307 | 0.050 |
Why?
| | United States | 3 | 2025 | 15966 | 0.050 |
Why?
| | Algorithms | 2 | 2021 | 1837 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2025 | 478 | 0.050 |
Why?
| | Middle Aged | 4 | 2025 | 35875 | 0.050 |
Why?
| | Consensus | 1 | 2024 | 488 | 0.050 |
Why?
| | Atrophy | 1 | 2022 | 201 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2023 | 214 | 0.040 |
Why?
| | Graft Survival | 1 | 2024 | 526 | 0.040 |
Why?
| | Complement C5 | 1 | 2020 | 33 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2029 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 2115 | 0.040 |
Why?
| | Radiography | 1 | 2022 | 844 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 548 | 0.040 |
Why?
| | Forms and Records Control | 1 | 2019 | 20 | 0.040 |
Why?
| | Information Services | 1 | 2019 | 46 | 0.040 |
Why?
| | Pregnenolone | 1 | 2019 | 3 | 0.040 |
Why?
| | Gelatinases | 1 | 2019 | 6 | 0.040 |
Why?
| | Fibrinogen | 1 | 2020 | 177 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 129 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 330 | 0.040 |
Why?
| | Cystatin C | 1 | 2019 | 65 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3863 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2019 | 312 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2019 | 147 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2019 | 116 | 0.040 |
Why?
| | Flavonoids | 1 | 2019 | 87 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1720 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2925 | 0.030 |
Why?
| | Allografts | 1 | 2019 | 150 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 614 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2019 | 251 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2947 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 157 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 556 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2015 | 114 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 916 | 0.030 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2014 | 25 | 0.030 |
Why?
| | Valsartan | 1 | 2014 | 32 | 0.030 |
Why?
| | Complement Hemolytic Activity Assay | 1 | 2013 | 2 | 0.030 |
Why?
| | Tetrazoles | 1 | 2014 | 50 | 0.030 |
Why?
| | Valine | 1 | 2014 | 80 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2013 | 27 | 0.030 |
Why?
| | Angiotensin II | 1 | 2014 | 97 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2014 | 78 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3162 | 0.020 |
Why?
| | Veterans | 1 | 2025 | 1603 | 0.020 |
Why?
| | Leupeptins | 1 | 2012 | 12 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 415 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2012 | 40 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1047 | 0.020 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2012 | 33 | 0.020 |
Why?
| | Transcription Factor CHOP | 1 | 2012 | 32 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 86 | 0.020 |
Why?
| | Everolimus | 1 | 2012 | 111 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5868 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5960 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 779 | 0.020 |
Why?
| | Pregnancy | 1 | 2005 | 7190 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 389 | 0.020 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2012 | 139 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 238 | 0.020 |
Why?
| | Multiprotein Complexes | 1 | 2012 | 172 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3185 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1382 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2013 | 395 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 60 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3077 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2010 | 149 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 449 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6429 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1833 | 0.020 |
Why?
| | Calcium | 1 | 2014 | 1183 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1732 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2014 | 2496 | 0.020 |
Why?
| | Proteins | 1 | 2012 | 1021 | 0.010 |
Why?
| | Aged | 1 | 2025 | 25913 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2012 | 2194 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 7173 | 0.010 |
Why?
|
|
Dixon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|